Research programme: Cannabidiol therapeutics - Phytecs

Drug Profile

Research programme: Cannabidiol therapeutics - Phytecs

Alternative Names: 4'-F-CBD; Fluorinated cannabidiol; HUF 101; HUF 102; HUF 103

Latest Information Update: 01 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Universidade Federal do Rio Grande do Sul; University of Sao Paulo; Yissum Research Development Company
  • Class Cannabinoids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anxiety disorders; Depressive disorders; Obsessive-compulsive disorders; Psychotic disorders

Most Recent Events

  • 22 Feb 2017 Phytec and Yissum Research Development agree to co-develop Cannabidiol therapeutics
  • 09 Aug 2016 Preclinical trials in Anxiety disorders in USA (unspecified route)
  • 09 Aug 2016 Preclinical trials in Depressive disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top